Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Zoetis Inc.

Zoetis is a self-described world's leading animal health company that develops and manufactures medicines, vaccines, diagnostics, and technologies for animals. The company has been operating for over 70 years, focusing on predicting, preventing, detecting, and treating animal illnesses.

Zoetis

Zoetis Business Consulting

My Retail Focus

The world’s leading animal health company. Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals.

We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries.

Community Guidelines:
This page is intended for learning more about how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are some guidelines to which posts and comments on this page must adhere.

If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET.

We reserve the right to remove any post/comment that violates LinkedIn Guidelines. We respectfully request that you refrain from posting comments including:

Unsolicited and/or unverified medical advice
Vulgarity and/or profanity
Discriminatory and/or derogatory comments, hate speech
Politics and religion
Personal attacks and/or threats
Promotion of illegal activity
Copyright/trademark infringements
Topics that may be considered spam/advertising

Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Last week we announced outstanding second quarter results, demonstrating the dedication of our purpose-driven colleagues and strong demand for our innovative products. Learn more about our Q2 financial results: https://lnkd.in/eEtid-6v

#FinancialResults #AnimalHealth

Each year, Zoetis colleagues celebrate Purpose Month in July — a time to come together as One Zoetis and make a difference among our colleagues, customers and communities.

We recently wrapped up the month with a celebratory event, where our executive team alongside hundreds of colleagues at Zoetis Headquarters had the opportunity to create comfort kits for service members, in partnership with the American Red Cross. Colleagues based in Malvern, PA and Durham, NC also joined in on this effort. These comfort kits bring a touch of home and healing to these service members, and it was an honor to bring Purpose Month to life through this volunteer activity.

#ZoetisProud #LivingOurPurpose #Volunteering

We’re pleased to announce outstanding second quarter results. Learn more and read the full press release here: https://lnkd.in/e9w5ecBz
 
#Earnings #AnimalHealth

2024 marks our largest cohort ever of interns – we are fortunate to have 150+ talented young professionals across the U.S. and around the world joining us this summer to support many different departments.

For National Intern Day this past Thursday, we celebrated by inviting our interns from New Jersey, New York, and Connecticut to our Parsippany HQ office to join CEO, Kristin Peck, and CFO, Wetteny Joseph, for a special Purpose Month volunteer activity and lunch.

The group came together to make greeting cards, pet toys and giveaways bags that will be donated to the Senior Paw Project, part of the Catherine Violet Hubbard Animal Sanctuary that supports senior pet owners in need of additional help caring for their beloved animals.
 
Thank you to our entire Zoetis intern class of 2024 – we look forward to seeing all the amazing things you will achieve!

Education and training are crucial to the A.L.P.H.A. Plus initiative as it progresses in supporting the establishment of sustainable veterinary care in Sub-Saharan Africa.
 
We're committed to training 100,000 professionals, including farmers, in Sub-Saharan Africa by the end of 2025. As women play a very important role in the region’s smallholder farms, we're focused on being gender intentional to increase female participation in training activities.
 
Learn more about our A.L.P.H.A. Plus initiative: https://lnkd.in/e65iXMeZ

#SustainableFarming #FoodSecurity #VeterinaryMedicine

Next week on August 6th, join our CEO, Kristin Peck and CFO, Wetteny Joseph, for the presentation of our second quarter 2024 #FinancialResults. Register for the live webcast below.

msh id	COM:ZOETIS
symbol	ZTS
name	Zoetis Inc.
homepage url	https://www.zoetis.com
country	US
sector	Healthcare
industry	Drug Manufacturers - Specialty & Generic
market	STOCKS
employee count	14.1K
crunchbase url	-
linkedin url	-
founders	-

market cap	79.16B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	457
monthly webtraffic growth	-0.79
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.06
growth cost of revenue	0.1
growth depreciation and amortization	2.27
growth ebitda	0.17
growth ebitda ratio	0.11
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-1
growth gross profit	0.04
growth gross profit ratio	-0.02

COM:ZOETIS

Zoetis

Last Close

175.67

21/11 21:00

Market Cap

79.16B

Beta: -

Volume Today

1.69M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	5.48B
cost of revenue	5.48B
depreciation and amortization	491M
ebitda	3.56B
ebitda ratio	0.42
eps	5.08
eps diluted	5.07
operating expenses	2.77B
operating income	3.07B
operating income ratio	0.36

accounts receivables	-102M
capital expenditure	-732M
cash at beginning of period	3.58B
cash at end of period	2.04B
inventory	2.56B
working capital ttm	4.61B

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-